European Archives - Page 23 of 1363 - European Medical Journal

Two people making a handshake

J&J acquires Halda to take on cancer cell resistance

J&J successfully acquired Halda Therapeutics for $3.05bn integrating Halda’s RIPTAC platform into J&J’s oncology portfolio.

cardiovascular disease

Semaglutide Reduces Hospital Admissions in Patients with Cardiovascular Disease

The results suggest that treatment once weekly with semaglutide could reduce the frequency and duration of hospital admissions for patients at high cardiovascular risk…

2026: Workforce, digital policy changes at NHS England

2026 is Pivotal for the NHS Workforce, Digital Policy

In 2026, the beleaguered, aging National Health Service (NHS) of England is on the precipice of major changes in staffing models and digital implementations.

AML

Targeted Aptamer Delivery Enhances AML Chemotherapy

An optimised OFA/iLRP aptamer forms a DNA nanostructure delivering doxorubicin selectively to AML cells, improving efficacy and reducing toxicity in preclinical models.

Social Determinants Drive Paediatric Long COVID Risk - EMJ

Social Determinants Drive Paediatric Long COVID Risk

Children facing economic instability and poor social support in the USA have higher odds of long COVID, highlighting the role of social determinants in child health.

Inflammatory Biomarker in Diabetic Nephropathy - EMJ

Neutrophil-to-Lymphocyte Ratio as Biomarker in Diabetic Nephropathy

39 studies involving 14 300 participants showed that patients with diabetic nephropathy had significantly elevated NLR levels compared to diabetic controls without nephropathy.

GIANT 2025 Interview: Rajesh Sivaprakasam

This is an area that I am very passionate about, particularly patient safety in the operating room. In the UK, there has been an increasing…

Cardiomyopathy

Polygenic Background Alters Risk of Cardiomyopathy

An increased polygenic score for HCM was associated with an 1.1% increase in left ventricular ejection fraction…

Pharma R&D cycle

End of lifelong pills? GSK’s phase 3 success in hepatitis B

GSK announced in January that its novel chronic hepatitis B successfully met primary goals in two pivotal phase 3 trials.

Vaccine administration

US slashes vaccine schedule: a major shift for paediatrics

CDC has formally reduced its routine childhood vaccine recommendations from 17 to 11, marking a major shift in US healthcare, read more.